Run-Hong Zhou1, Le Guo, Jin-Biao Liu, Hang Liu, Wei Hou, Tong-Cui Ma, Xu Wang, Jian-Guo Wu, Li Ye, Wen-Zhe Ho, Jie-Liang Li. 1. *School of Basic Medical Sciences/State Key Laboratory of Virology, Wuhan University, Wuhan, China; †Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA; and ‡School of Public Health, Guangxi Medical University, Nanning, China.
Abstract
BACKGROUND: Human semen contains a factor that can enhance HIV infection up to 10-fold in cultures. This factor is termed semen-derived enhancer of virus infection (SEVI) and is composed of proteolytic fragments (PAP248-286) from prostatic acid phosphatase in semen. In this study, we examined whether macaque SEVI can facilitate simian immunodeficiency virus (SIV) or chimeric simian/human immunodeficiency virus (SHIV) infection. We also studied the effect of epigallocatechin gallate (EGCG) on macaque SEVI-mediated SIV or SHIV enhancement. METHODS: SIV or SHIV was mixed with different concentrations of macaque SEVI in the presence or absence of EGCG. The mixture was added to cultures of TZM-bl cells or macaque PBMCs. The effect of EGCG on macaque SEVI was measured by Congo-red staining assay and thioflavin T (ThT) fluorescence assay and was visualized by a transmission electron microscope. RESULTS: We identified that there is one amino acid difference at the site of 277 between human PAP248-286 and macaque PAP248-286. Macaque SEVI significantly enhanced SIV or SHIV infection of TZM-bl cells and macaque PBMCs. EGCG could block macaque SEVI-mediated enhancement of SIV or SHIV infection. Mechanistically, EGCG could degrade the formation of macaque SEVI amyloid fibrils that facilitates HIV attachment to the target cells. CONCLUSIONS: The finding that macaque SEVI could enhance SIV or SHIV infection indicates the possibility to use the macaque SEVI in vivo studies with the macaque models. In addition, future studies are necessary to examine whether EGCG can be used as an effective microbicide for preventing SIV or SHIV mucosal transmission.
BACKGROUND:Human semen contains a factor that can enhance HIV infection up to 10-fold in cultures. This factor is termed semen-derived enhancer of virus infection (SEVI) and is composed of proteolytic fragments (PAP248-286) from prostatic acid phosphatase in semen. In this study, we examined whether macaque SEVI can facilitate simian immunodeficiency virus (SIV) or chimeric simian/human immunodeficiency virus (SHIV) infection. We also studied the effect of epigallocatechin gallate (EGCG) on macaque SEVI-mediated SIV or SHIV enhancement. METHODS:SIV or SHIV was mixed with different concentrations of macaque SEVI in the presence or absence of EGCG. The mixture was added to cultures of TZM-bl cells or macaque PBMCs. The effect of EGCG on macaque SEVI was measured by Congo-red staining assay and thioflavin T (ThT) fluorescence assay and was visualized by a transmission electron microscope. RESULTS: We identified that there is one amino acid difference at the site of 277 between humanPAP248-286 and macaque PAP248-286. Macaque SEVI significantly enhanced SIV or SHIV infection of TZM-bl cells and macaque PBMCs. EGCG could block macaque SEVI-mediated enhancement of SIV or SHIV infection. Mechanistically, EGCG could degrade the formation of macaque SEVI amyloid fibrils that facilitates HIV attachment to the target cells. CONCLUSIONS: The finding that macaque SEVI could enhance SIV or SHIV infection indicates the possibility to use the macaque SEVI in vivo studies with the macaque models. In addition, future studies are necessary to examine whether EGCG can be used as an effective microbicide for preventing SIV or SHIV mucosal transmission.
Authors: A Tachet; E Dulioust; D Salmon; M De Almeida; S Rivalland; L Finkielsztejn; I Heard; P Jouannet; D Sicard; C Rouzioux Journal: AIDS Date: 1999-05-07 Impact factor: 4.177
Authors: Ravi P R Nanga; Jeffrey R Brender; Subramanian Vivekanandan; Nataliya Popovych; Ayyalusamy Ramamoorthy Journal: J Am Chem Soc Date: 2009-12-16 Impact factor: 15.419
Authors: S C Kalichman; M Cage; T Barnett; P Tharnish; D Rompa; J Austin; W Luke; J O'Mowrey; R F Schinazi Journal: AIDS Res Hum Retroviruses Date: 2001-12-10 Impact factor: 2.205
Authors: Ilona Hauber; Heinrich Hohenberg; Barbara Holstermann; Werner Hunstein; Joachim Hauber Journal: Proc Natl Acad Sci U S A Date: 2009-05-18 Impact factor: 11.205
Authors: Woj M Wojtowicz; Michael Farzan; John L Joyal; Kara Carter; Gregory J Babcock; David I Israel; Joseph Sodroski; Tajib Mirzabekov Journal: J Biol Chem Date: 2002-07-15 Impact factor: 5.157
Authors: Nadia R Roan; Jan Münch; Nathalie Arhel; Walther Mothes; Jason Neidleman; Akiko Kobayashi; Karen Smith-McCune; Frank Kirchhoff; Warner C Greene Journal: J Virol Date: 2008-10-22 Impact factor: 5.103
Authors: Jan Münch; Elke Rücker; Ludger Ständker; Knut Adermann; Christine Goffinet; Michael Schindler; Steffen Wildum; Raghavan Chinnadurai; Devi Rajan; Anke Specht; Guillermo Giménez-Gallego; Pedro Cuevas Sánchez; Douglas M Fowler; Atanas Koulov; Jeffery W Kelly; Walther Mothes; Jean-Charles Grivel; Leonid Margolis; Oliver T Keppler; Wolf-Georg Forssmann; Frank Kirchhoff Journal: Cell Date: 2007-12-14 Impact factor: 41.582
Authors: J B Liu; J L Li; K Zhuang; H Liu; X Wang; Q H Xiao; X D Li; R H Zhou; L Zhou; T C Ma; W Zhou; M Q Liu; W Z Ho Journal: Mucosal Immunol Date: 2018-05-31 Impact factor: 7.313